(Q42627337)

4 November 2017

0 references

Incretins: clinical physiology and bariatric surgery--correlating the entero-endocrine system and a potentially anti-dysmetabolic procedure (English)

1 reference

4 November 2017

0 references

Rodrigo N Lamounier

1

1 reference

4 November 2017

José Carlos Pareja

series ordinal

2

1 reference

4 November 2017

Marcos Antonio Tambascia

series ordinal

3

1 reference

4 November 2017

Bruno Geloneze

series ordinal

4

1 reference

4 November 2017

publication date

1 May 2007

1 reference

4 November 2017

1 reference

4 November 2017

volume

17

1 reference

4 November 2017

issue

5

1 reference

4 November 2017

page(s)

569-576

1 reference

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

4 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11695-007-9098-Y

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11695-007-9098-Y

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11695-007-9098-Y

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

12 December 2020

A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans

1 reference

12 December 2020

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

1 reference

12 December 2020

GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts

1 reference

12 December 2020

Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery

1 reference

12 December 2020

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

1 reference

12 December 2020

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.

1 reference

12 December 2020

Role of leptin in the regulation of glucagon-like peptide-1 secretion

1 reference

12 December 2020

Entero-insular axis and diabetes mellitus

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Molecular and anatomical determinants of central leptin resistance

1 reference

12 December 2020

Ghrelin: a gut-brain hormone: effect of gastric bypass surgery

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.

1 reference

12 December 2020

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

1 reference

12 December 2020

The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes

1 reference

12 December 2020

Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations.

1 reference

12 December 2020

The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery.

1 reference

12 December 2020

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

1 reference

12 December 2020

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

1 reference

12 December 2020

Elevated plasma ghrelin levels in Prader–Willi syndrome

1 reference

12 December 2020

Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes

1 reference

12 December 2020

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

12 December 2020

Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus.

1 reference

12 December 2020

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

1 reference

12 December 2020

Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery

1 reference

12 December 2020

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

12 December 2020

Gastric inhibitory polypeptide: the neglected incretin revisited

1 reference

12 December 2020

Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats

1 reference

12 December 2020

Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight

1 reference

12 December 2020

A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding

1 reference

12 December 2020

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

1 reference

12 December 2020

Gastric satiation is volumetric, intestinal satiation is nutritive

1 reference

12 December 2020

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

12 December 2020

Peptide YY(1-36) and peptide YY(3-36): Part II. Changes after gastrointestinal surgery and bariatric surgery

1 reference

12 December 2020

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

12 December 2020

Amelioration of diet-induced diabetes mellitus by removal of visceral fat.

1 reference

12 December 2020

Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin

1 reference

12 December 2020

Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion

1 reference

12 December 2020

Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss

1 reference

12 December 2020

Biological actions and therapeutic potential of the glucagon-like peptides

1 reference

12 December 2020

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

12 December 2020

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

1 reference

12 December 2020

A role for glucagon-like peptide-1 in the central regulation of feeding

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

12 December 2020

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

1 reference

12 December 2020

Short-term changes in insulin resistance following weight loss surgery for morbid obesity: laparoscopic adjustable gastric banding versus laparoscopic Roux-en-Y gastric bypass

1 reference

12 December 2020

Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass

1 reference

12 December 2020

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

1 reference

12 December 2020

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype

1 reference

12 December 2020

DPP-4 inhibitors and their potential role in the management of type 2 diabetes

1 reference

12 December 2020

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

1 reference

12 December 2020

Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia

1 reference

12 December 2020

Direct stimulation of ghrelin secretion by sympathetic nerves

1 reference

12 December 2020

Laparoscopic sleeve gastrectomy with ileal interposition ("neuroendocrine brake")--pilot study of a new operation

1 reference

12 December 2020

Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects.

1 reference

12 December 2020

Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery.

1 reference

12 December 2020

Type 2 diabetes and weight loss following biliopancreatic diversion for obesity

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

12 December 2020

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

12 December 2020

Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

12 December 2020

10.1007/S11695-007-9098-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

4 November 2017

1004153580

0 references

1 reference